Ultragenyx Pharmaceutical | RARE - Assets


Ultragenyx Pharmaceutical reported $1.53B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
BioCryst Pharmaceuticals USD 446.42M 10.76M Sep/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
Immunic USD 40.7M 20.72M Sep/2025
Insmed USD 2.26B 96.18M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
Kyowa Hakko Kirin JPY 1.11T 30.41B Dec/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Moderna USD 12.34B 203M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xoma USD 263.15M 39.7M Sep/2025